AuthorisedTherapeutic use (Phase IV)Interventional

A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum

This study, called "A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum," is designed for people living with obesity. It specifically looks at how a medication called Wegovy (semaglutide at 2.4 mg) affects participants. Researchers are interested in seeing how much a person's weight and Body Mass Index (BMI) change after six months of using Wegovy. They are also carefully tracking any changes in binge eating patterns, using a special scale called the Binge Eating Scale (BES). This research aims to understand not only if Wegovy works for weight management and binge eating, but also if certain biological and psychological factors can help predict who might benefit most from this treatment. It's a post-market study, meaning Wegovy is already approved, and this research gathers more information on its use.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

UZ Leuven

Enrolment target

Start

08 Jun 2026

obesity

What is this study about?

This research is looking into a medication called Wegovy, which is an injection taken for weight management. Doctors are already prescribing it, and this study aims to learn more about how it works, especially for people who have obesity and also deal with binge eating. Think of it like taking a closer look at a tool that's already in use to see if it can be made even more effective for specific people.

The main goal is to understand how much a person's weight changes after six months of using Wegovy. They will also be tracking any improvements in binge eating habits during this time. Beyond just weight loss, the study is also checking lots of other things that might be connected to weight and binge eating, like body shape, what the body is made of (muscle vs. fat), blood levels of certain hormones, and even how the brain reacts to food.

By gathering all this detailed information, scientists hope to figure out if there are specific signs, either in our bodies or in how our brains work, that could help doctors know who would benefit most from Wegovy. Ultimately, this could mean that in the future, doctors can choose the best weight management treatment for each individual person, making care more tailored and effective.

Key takeaways

This study evaluates Wegovy (a weight management injection) for people with obesity.
It specifically investigates its effects on weight loss and binge eating over six months.
Researchers are also looking for biological and brain signals to predict who benefits most.
It's a Phase IV study, meaning Wegovy is already approved for use.
Adults (18+) with obesity are eligible to participate.
The goal is to personalize future weight management treatments.

Who may be eligible?

To be part of this study, you need to be an adult, aged 18 or older – there's no upper age limit. The study is open to both men and women.

Since this study is specifically about weight management and a condition called obesity, you would need to be diagnosed with obesity to be considered. Remember, being eligible for a study means meeting certain health criteria and other conditions that the research team sets to make sure the study is safe and effective for everyone involved.

It's important to know that while these are the basic requirements, there will be other specific things the research team will look for during a screening process. These could include your current health conditions, other medications you might be taking, and past medical history. They need to ensure that taking part is suitable and safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Am I 18 years old or older?
Have I been diagnosed with obesity?
Am I comfortable with injections for medication?
Can I commit to regular study visits for at least six months?
Am I willing to have various health checks, including blood tests and possibly scans?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would receive the medication Wegovy, which is given as an injection. The study will last for at least six months. During this time, you will have regular visits with the study team. At these visits, they will check your progress, take various measurements like your weight, and ask you questions about your eating habits and how you are feeling.

These measurements might include things like blood tests, urine tests, and possibly specialized scans to understand your body composition or how your brain responds to food. You would be expected to follow the treatment plan for the full six months. The total duration of your involvement could be slightly longer to allow for initial checks and final assessments.

Potential risks and benefits

Taking part in this study could offer several potential benefits, such as receiving the study medication, Wegovy, which may help with weight management and potentially reduce binge eating. You'd also get close medical monitoring and care from the study team. However, like all medications, Wegovy has potential side effects, which can include nausea, vomiting, diarrhoea, constipation, and stomach pain, among others. There might be other risks associated with the assessments, such as minor discomfort from blood tests. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Belgium

Common questions

What is Wegovy?

Wegovy is a medication that helps with weight management. It's given as an injection and works by making you feel fuller and less hungry.

What is 'binge eating'?

Binge eating is when a person eats a very large amount of food in a short time, often feeling a loss of control during the episode. This study looks at if Wegovy can help with this.

How long will I be in the study?

The main treatment part of the study where you take Wegovy will last for six months. There might be some checks before and after this period.

Will I have to pay to be in the study?

Clinical trials generally do not charge participants for the study medication or related medical care. Any related costs would likely be covered by the study sponsor, but this should be confirmed with the study team.

What happens if I change my mind?

You are free to leave the study at any time, for any reason. Your decision will not affect your relationship with your doctor or your ongoing medical care.